Vistagen Presents Positive Phase 3 Candidate Data for Social Anxiety Disorder
Steady: 0 in the last 7 days
Updated oct 20
The latest in this situation
How it started
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vistagen presented positive exploratory results for fasedienol nasal spray at Psych Congress 2026. The product is a rapid-onset Phase 3 candidate designed for individuals with very severe social anxiety disorder. The research showed that participants in specific subgroups experienced improvements in anxiety symptoms following treatment compared with placebo.
From manilatimes.net
Why it matters
Positive potential efficacy signals for fasedienol in this patient population are encouraging for the drug's commercial viability. The findings contribute to the overall body of evidence used by the FDA for future product evaluation and approval.
From manilatimes.net
Who's involved
- FDARegulatory body responsible for product evaluation and approval
How it developed
Newest first. Tap a step to see who reported it.- GATC Health and Vistagen have collaborated to combine neuroscience and predictive modeling for drug development.Sub-event
Vistagen is involved in developing a late-stage biopharma product.1 source